Quick Answer
Imunon, Inc. reported Total Revenue of $500.0 thousand for the year ending 2022.
- Imunon, Inc. showed an increase of +0.0% in Total Revenue from 2021 to 2022.
- This data is from Imunon, Inc.'s annual report (Form 10-K), filed with the SEC on March 28, 2024.
- XBRL data for this metric is available from 2017 to 2022 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $125.0 thousand | Q1 2018: $125.0 thousand | Q2 2018: $125.0 thousand | Q3 2018: $125.0 thousand | Q1 2019: $125.0 thousand | Q2 2019: $125.0 thousand | Q3 2019: $125.0 thousand | Q1 2020: $125.0 thousand | Q2 2020: $125.0 thousand | Q3 2020: $125.0 thousand | Q1 2021: $125.0 thousand | Q2 2021: $125.0 thousand | Q3 2021: $125.0 thousand | Q1 2022: $125.0 thousand | Q2 2022: $125.0 thousand | Q3 2022: $125.0 thousand.
- Over the full 6 years of available data (2017 to 2022), Imunon, Inc.'s Total Revenue has grown by 0.0%.
- Historical annual values: Fiscal year 2022: $500.0 thousand | Fiscal year 2021: $500.0 thousand | Fiscal year 2020: $500.0 thousand | Fiscal year 2019: $500.0 thousand | Fiscal year 2018: $500.0 thousand | Fiscal year 2017: $500.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: